Table 3.
Bone turnover markers.
| Capecitabine + Ra223 n = 23 |
Capecitabine N = 11 |
|
|---|---|---|
| NTX | ||
| Median baseline NTX BCE/mmolCr (range) | 16 (7–35) | 17 (7–143) |
| Baseline NTX ≥ 50 BCE/mmolCr | 0/21 (0%) | 2/11 (18%) |
| Median % change from baseline at end of cycle 5, range | +16% (14 available), (-66%, 67%) |
−6% (7 available), (-29%, 147%) |
| NTX responder | 3/16 (19%) | 2/8 (25%) |
| CTX | ||
| Median baseline CTX (range) ng/ml | 0.08 (0.05–0.19) | 0.10 (0.05–0.58) |
| Baseline CTX ≥ 0.15 ng/ml | 2/22 (9%) | 2/11 (18%) |
| Median % change from baseline at end of cycle 5, range | −2% (15 available), (-27%, 521%) |
−7% (9 available), (-39%, 20%) |
| CTX responder | 0/18 | 1/10 (10%) |
| PINP | ||
| Median baseline PINP ng/ml (range) | 48 (8–149) | 109 (26 – 356) |
| PINP ≥ 60 ng/ml | 9/22 (41%) | 8/11 (73%) |
| Median % change from baseline at end of cycle 5, range | −9% (15 available), (-93%, 118%) |
−39% (9 available), (-75%, 171%) |
| PINP responder | 7/18 (39%) | 6/10 (60%) |
| B-ALP | ||
| Median baseline B-ALP ng/ml (range) | 17.2 (7.2 – 39.4) | 28.6 (12.5 – 63.5) |
| B-ALP ≥ 25 ng/ml | 3/22 (14%) | 5/9 (56%) |
| Median % change from baseline at end of cycle 5, range | −5% (15 available), (−72%, 108%) |
+5% (6 available), (-68%, 78%) |
| B-ALP responder | 4/18 (22%) | 2/7 (29%) |